Table 2.
Unadjusted Patient Outcomes at 28 Days After Presentation to Care by Statin Treatment Group (N = 1179)
| Outcome | Patients, No. With Characteristic/No. in Statin Treatment Group (%)a | P Valueb | |||
|---|---|---|---|---|---|
| Group A: Continued (n=466) | Group B: Discontinued (n=42) | Group C: Newly Initiated (n=311) | Group D: Never (n=360) | ||
| Patient status at 28 d | |||||
| Deceasedc | 78/466 (16.7) | 14/42 (33.3) | 30/311 (9.6) | 32/360 (8.9) | <.001 |
| Discharged alive | 252/466 (54.1) | 20/42 (47.6) | 176/311 (56.6) | 257/360 (71.4) | <.001 |
| Transfer to other facility (nonpalliative care) | 61/466 (13.1) | 4/42 (9.5) | 36/311 (11.6) | 35/360 (9.7) | <.001 |
| Still hospitalized at 28 d | 75/466 (16.1) | 4/42 (9.5) | 69/311 (22.2) | 36/360 (10.0) | <.001 |
| Time from hospital admission to death, median (IQR), d | 10 (6–15) [n=78] | 3 (1–4) [n=14] | 12 (7–16) [n=30] | 6 (3–13) [n=32] | <.001 |
| Time from hospital admission to discharge or transfer, median (IQR), d | 7 (4–10) [n=313] | 4 (1–6) [n=24] | 7 (4–10) [n=212] | 5 (3–8) [n=292] | <.001 |
| Patient events during 28-d follow-up | |||||
| ICU admission | 145/466 (31.1) | 8/42 (19.0) | 131/311 (42.1) | 77/360 (21.4) | <.001 |
| Invasive intubation | 122/466 (26.2) | 6/42 (14.3) | 110/311 (35.4) | 65/360 (18.1) | <.001 |
| Bacterial pneumonia | 132/466 (28.3) | 9/42 (21.4) | 106/311 (34.1) | 71/360 (19.7) | <.001 |
| ARDS | 112/466 (24.0) | 5/42 (11.9) | 105/311 (33.8) | 61/360 (16.9) | <.001 |
| Stroke/CVA | 3/466 (0.6) | 1/42 (2.4) | 3/311 (1.0) | 2/360 (0.6) | .39 |
| Cardiac arrest | 2/466 (0.4) | 1/42 (2.4) | 2/311 (0.6) | 2/360 (0.6) | .39 |
| Rhabdomyolysis/myositis | 18/466 (3.9) | 2/42 (4.8) | 18/311 (5.8) | 21/360 (5.8) | .50 |
| Liver dysfunction | 80/466 (17.2) | 11/42 (26.2) | 71/311 (22.8) | 64/360 (17.8) | .12 |
Abbreviations: ARDS, acute respiratory distress syndrome; CVA, cerebrovascular accident; ICU, intensive care unit; IQR, interquartile range.
Data represent no. with characteristic/no. in statin treatment group (%), unless otherwise specified. Treatment groups were defined as follows: group A, antecedent (prehospitalization) statin continued during hospitalization (Continued); group B, antecedent statin discontinued during hospitalization (Discontinued); group C, statin newly initiated during hospitalization (Newly Initiated); and group D, no statins used during or before hospitalization (Never).
P values were calculated comparing all 4 groups, using the Kruskal-Wallis test for continuous variables and Fisher exact test for categorical variables.
Deceased patients include 3 who were discharged to hospice care.